PEX11A

Across TCGA pan-cancer cohorts, PEX11A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PEX11A data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PEX11A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PEX11A expression acts as an unfavorable survival marker.

OV and PRAD are the cancer types where PEX11A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.289	0.843	<.001	48	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PEX11A–OV (OS)

Open the OV breakdown →